Latest News “Nature Biotechnology: COVID-19 long haulers” Click here. “Ampio gets promising data on drug that could be used to treat COVID” Click here. Ampio Pharmaceuticals to Host Business Update Call with Chairman and CEO Mike Martino on Wednesday, Dec. 1Date: November 29, 2021 | READ MORE > Ampio Pharmaceuticals Announces Shareholder / Business Update Call with its CEO & Chairman, Michael MartinoDate: November 23, 2021 | READ MORE > Board Member Michael Martino to Become Interim Chairman and CEO of Ampio Pharmaceuticals, Mike Macaluso to Take Medical LeaveDate: November 22, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides Business UpdateDate: November 10, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Business UpdateDate: October 28, 2021 | READ MORE > Ampio Pharmaceuticals Strengthens Management Team and Board of DirectorsDate: October 13, 2021 | READ MORE > Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in IndiaDate: September 21, 2021 | READ MORE > Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)Date: September 15, 2021 | READ MORE > Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of ActionDate: August 13, 2021 | READ MORE > Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual MeetingDate: August 12, 2021 | READ MORE > Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor ConferencesDate: August 11, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateDate: August 4, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the American College of Toxicology 42nd Annual MeetingDate: July 29, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA)Date: July 28, 2021 | READ MORE > Ampio Pharmaceuticals to Present at Aspen Lung ConferenceDate: July 27, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business UpdateDate: July 14, 2021 | READ MORE > Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory DistressDate: June 25, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® IndexDate: June 18, 2021 | READ MORE > Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAKDate: June 17, 2021 | READ MORE > Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to IndiaDate: June 15, 2021 | READ MORE >
